Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
xCures
Dysplasia Diagnostics Limited
GlaxoSmithKline
Telix Pharmaceuticals (Innovations) Pty Limited
Celgene
Novo Nordisk A/S
Celgene
Gilead Sciences
Shenzhen BinDeBio Ltd.
SpeciCare
Polaris Group
Shenzhen BinDeBio Ltd.
Angiochem Inc
INSYS Therapeutics Inc
Pfizer